IL17A and plasma cell myeloma: Notably, four clinical trials on myeloma, diffuse large B cell lymphoma (DLBCL), melanoma, and NSCLC are ongoing which combine anti-PD1 antibody and IL-17A (NCT03111992), CD22 (NCT03287817), KIT (NCT04493203), or AXL (NCT04681131), respectively (Fig. 4F).